Unknown

Dataset Information

0

O-GlcNAc cycling mutants modulate proteotoxicity in Caenorhabditis elegans models of human neurodegenerative diseases.


ABSTRACT: O-GlcNAcylation is an abundant posttranslational modification in the brain implicated in human neurodegenerative diseases. We have exploited viable null alleles of the enzymes of O-GlcNAc cycling to examine the role of O-GlcNAcylation in well-characterized Caenorhabditis elegans models of neurodegenerative proteotoxicity. O-GlcNAc cycling dramatically modulated the severity of the phenotype in transgenic models of tauopathy, amyloid ?-peptide, and polyglutamine expansion. Intriguingly, loss of function of O-GlcNAc transferase alleviated, whereas loss of O-GlcNAcase enhanced, the phenotype of multiple neurodegenerative disease models. The O-GlcNAc cycling mutants act in part by altering DAF-16-dependent transcription and modulating the protein degradation machinery. These findings suggest that O-GlcNAc levels may directly influence neurodegenerative disease progression, thus making the enzymes of O-GlcNAc cycling attractive targets for neurodegenerative disease therapies.

SUBMITTER: Wang P 

PROVIDER: S-EPMC3491483 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

O-GlcNAc cycling mutants modulate proteotoxicity in Caenorhabditis elegans models of human neurodegenerative diseases.

Wang Peng P   Lazarus Brooke D BD   Forsythe Michele E ME   Love Dona C DC   Krause Michael W MW   Hanover John A JA  

Proceedings of the National Academy of Sciences of the United States of America 20120917 43


O-GlcNAcylation is an abundant posttranslational modification in the brain implicated in human neurodegenerative diseases. We have exploited viable null alleles of the enzymes of O-GlcNAc cycling to examine the role of O-GlcNAcylation in well-characterized Caenorhabditis elegans models of neurodegenerative proteotoxicity. O-GlcNAc cycling dramatically modulated the severity of the phenotype in transgenic models of tauopathy, amyloid β-peptide, and polyglutamine expansion. Intriguingly, loss of f  ...[more]

Similar Datasets

| S-EPMC7460676 | biostudies-literature
| S-EPMC3887457 | biostudies-literature
| S-EPMC2757632 | biostudies-literature
| S-EPMC2867743 | biostudies-literature
| S-EPMC6776490 | biostudies-literature
| S-EPMC4155875 | biostudies-literature
| S-EPMC1567679 | biostudies-literature
| S-EPMC8195402 | biostudies-literature
| S-EPMC6099907 | biostudies-other
| S-EPMC6793420 | biostudies-literature